EA201490707A1 - Макроциклические ингибиторы flt3-киназы - Google Patents

Макроциклические ингибиторы flt3-киназы

Info

Publication number
EA201490707A1
EA201490707A1 EA201490707A EA201490707A EA201490707A1 EA 201490707 A1 EA201490707 A1 EA 201490707A1 EA 201490707 A EA201490707 A EA 201490707A EA 201490707 A EA201490707 A EA 201490707A EA 201490707 A1 EA201490707 A1 EA 201490707A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flt3 kinase
macro cyclic
cyclic inhibitors
compounds
present
Prior art date
Application number
EA201490707A
Other languages
English (en)
Other versions
EA025881B1 (ru
Inventor
Петра Марселла Франсуаза Блом
Ян Мари Сирил Йозеф Хофлак
Original Assignee
Онкодизайн С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкодизайн С.А. filed Critical Онкодизайн С.А.
Publication of EA201490707A1 publication Critical patent/EA201490707A1/ru
Publication of EA025881B1 publication Critical patent/EA025881B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к макроциклическим соединениям и композициям, содержащим указанные соединения, действующим в качестве ингибиторов киназ, в частности в качестве ингибиторов FLT3 (FMS-родственной тирозинкиназы 3). Более того, настоящее изобретение предусматривает способы получения раскрытых соединений, а также способы их применения, к примеру, в качестве медикамента, в частности, для лечения клеточных пролиферативных нарушений, таких как рак.
EA201490707A 2011-09-30 2012-09-28 Макроциклические ингибиторы flt3-киназы EA025881B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011067084 2011-09-30
PCT/EP2012/069252 WO2013045653A1 (en) 2011-09-30 2012-09-28 Macrocyclic flt3 kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201490707A1 true EA201490707A1 (ru) 2014-08-29
EA025881B1 EA025881B1 (ru) 2017-02-28

Family

ID=46980944

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490707A EA025881B1 (ru) 2011-09-30 2012-09-28 Макроциклические ингибиторы flt3-киназы

Country Status (14)

Country Link
US (2) US9090630B2 (ru)
JP (1) JP6046728B2 (ru)
KR (1) KR20140078710A (ru)
CN (1) CN103930427B (ru)
AU (1) AU2012314376B2 (ru)
BR (1) BR112014007622A2 (ru)
CA (1) CA2849999A1 (ru)
DK (1) DK2760867T3 (ru)
EA (1) EA025881B1 (ru)
ES (1) ES2569048T3 (ru)
HK (1) HK1198764A1 (ru)
HU (1) HUE027318T2 (ru)
MX (1) MX347765B (ru)
WO (1) WO2013045653A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2583477T3 (es) * 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
JP2016510793A (ja) * 2013-03-15 2016-04-11 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． 大環状ｌｒｒｋ２キナーゼ阻害剤
US9586975B2 (en) * 2013-03-15 2017-03-07 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
MX2015012526A (es) * 2013-03-15 2016-04-26 Oncodesign Sa Inhibodores macrociclicos de cinasa rip2.
CA2911259A1 (en) * 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
SG10202000191YA (en) * 2014-01-24 2020-03-30 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
WO2015136073A1 (en) * 2014-03-14 2015-09-17 Oncodesign Sa Macrocyclic tgf-br2 kinase inhibitors
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
AU2015300782B2 (en) 2014-08-08 2020-04-16 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
BR112017004035B1 (pt) * 2014-09-17 2023-11-14 Oncodesign Precision Medicine (OPM) Inibidores macrocíclicos de rip2 quinase e composições farmacêuticas
EA032838B1 (ru) * 2014-09-17 2019-07-31 Онкодизайн С.А. Макроциклические ингибиторы lrrk2-киназы
WO2016146651A1 (en) 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
US10294242B2 (en) 2015-07-06 2019-05-21 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
AU2016296878B2 (en) 2015-07-21 2020-12-17 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
US10954242B2 (en) 2016-07-05 2021-03-23 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
KR20190034225A (ko) 2016-07-28 2019-04-01 티피 테라퓨틱스, 인크. 거대환 키나제 억제제
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
AU2018226771B2 (en) 2017-02-28 2023-11-23 Dana-Farber Cancer Institute, Inc. Uses of pyrimidopyrimidinones as SIK inhibitors
AU2018306328B2 (en) 2017-07-28 2023-03-09 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN111511746B (zh) 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
CN110950889B (zh) * 2018-09-27 2022-04-05 北京赛林泰医药技术有限公司 一种多靶点激酶抑制剂及其制备方法和用途
JP2023504523A (ja) * 2019-12-03 2023-02-03 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患処置に使用するための大環状分子

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
CN1110300C (zh) 1993-10-01 2003-06-04 阿斯特拉公司 工艺技术ⅰ
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
NZ595182A (en) 2005-10-18 2012-12-21 Janssen Pharmaceutica Nv Pharmaceutical uses of 4-cyano-1H-imidazole-2-carboxylic acid { 2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl} -amide
US20100016300A1 (en) 2006-08-02 2010-01-21 Ajami Alfred M Imidazoacridine Compounds for Treating FLT3-Mediated Disorders
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
EP2086979B1 (en) * 2006-11-06 2015-06-03 Tolero Pharmaceuticals, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
WO2009017795A1 (en) 2007-08-02 2009-02-05 Xanthus Pharmaceuticals, Inc. Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers
ES2494365T3 (es) 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
CN101239978A (zh) 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
ES2583477T3 (es) * 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2

Also Published As

Publication number Publication date
KR20140078710A (ko) 2014-06-25
ES2569048T3 (es) 2016-05-06
DK2760867T3 (en) 2016-04-11
WO2013045653A1 (en) 2013-04-04
HUE027318T2 (en) 2016-10-28
JP6046728B2 (ja) 2016-12-21
AU2012314376A1 (en) 2014-05-15
CA2849999A1 (en) 2013-04-04
AU2012314376B2 (en) 2017-04-06
US9370519B2 (en) 2016-06-21
US20140303159A1 (en) 2014-10-09
US20150283141A1 (en) 2015-10-08
CN103930427B (zh) 2016-03-09
MX347765B (es) 2017-05-12
CN103930427A (zh) 2014-07-16
JP2014528398A (ja) 2014-10-27
HK1198764A1 (zh) 2015-06-05
US9090630B2 (en) 2015-07-28
EA025881B1 (ru) 2017-02-28
BR112014007622A2 (pt) 2017-04-04
MX2014003807A (es) 2015-01-12

Similar Documents

Publication Publication Date Title
EA201490707A1 (ru) Макроциклические ингибиторы flt3-киназы
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201992270A2 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
EA201890333A1 (ru) Противовирусные соединения
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201490357A1 (ru) Индазолы
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201391416A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
IN2014KN02601A (ru)
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201500426A1 (ru) Производные пирролотриазинона в качестве ингибиторов pi3k
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201391106A1 (ru) Новые гетероциклические производные
EA201492002A1 (ru) Противовирусные соединения
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU